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Background: Klebsiella pneumoniae is one of the most important opportunistic pathogens causing serious complications
in patients in hospitals and community. The clinical significance of K. pneumoniae is mainly due to its ability to acquire
multiple antibiotic resistance genes. In this study we report the findings of a survey of plasmid mediated quinolone
resistance in Extended-Spectrum β-lactamase (ESBL)-producing K. pneumoniae in Kuwait.
Methods: Clinical samples were collected from the microbiology laboratories of three major hospitals. Isolates were
confirmed as ESBL-producers by disc diffusion method and PCR for the presence of bla genes. Antimicrobial
susceptibility testing and genetic analysis were performed to detect the presence of a number of genes conferring
resistance to β-lactam and fluoroquinolone antimicrobial agents including blaSHV, blaTEM, aac (6')-Ib-cr, qnrA, qnrB
and qnrS. Pulsed-field gel electrophoresis (PFGE) was used for typing the isolates.
Results: In total 173 ESBL-producing K. pneumoniae were detected. qnr genes were identified in 27 (15.6 %) isolates and
aac(6′)-Ib Ib-cr gene in 26 (96 %). One (3.7 %) contained qnrA2, 21 harbored qnrB1 (78 %) and 5 (18.5 %) contained qnrS.
Twenty one (78 %) isolates contained all three bla genes. PFGE showed diverse profiles.
Conclusion: We identified for the first time the emergence of the mobile fluoroquinolone resistance qnrA2 in a clinical
isolate in the middle east and also showed the dissemination of aac (6')-Ib-cr, qnrB, and qnrS genes among
ESBL-producing K. pneumoniae in Kuwait. The abundance of plasmid mediated resistance to fluoroquinolones
among ESBL-producing K. pneumoniae is alarming as it facilitates therapy failure. Preventing the spread of these
isolates is crucial if we are to sustain the effectiveness of the limited choices we have left in antimicrobial therapy.
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Members of the Enterobacteriaceae family in particular the
multi-drug resistant Klebsiella pneumoniae are amongst
the opportunistic pathogens. K. pneumoniae causes a wide
range of infections from urinary and respiratory tract infec-
tions to bacteraemia, particularly in elderly or debilitated
patients. Antibiotic resistance is an important factor that
hinders therapy and delays improvement in patients’ health.
In K. pneumoniae resistance to antimicrobial agents is* Correspondence: leila@hsc.edu.kw
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creativecommons.org/publicdomain/zero/1.0/caused by different mechanisms however the production of
extended spectrum β-lactamases (ESBLs) such as CTX-M
and other enzymes including TEM-1, TEM-24, SHV-12
and the plasmid-mediated AmpC (CMY-2) are considered
highly important [1–3]. CTX-M-15 producing strains can
often contain variants of an aminoglycoside-modifying
enzyme expressed by aac(6′)-Ib-cr genes. Aminoglycoside-
modifying enzymes cause reduced susceptibility to
aminoglycosides and to some fluoroquinolones [4].
Fluoroquinolone resistance in K. pneumoniae can arise
by mutations in the chromosomal type II topoisomerases
and changes in the expression of efflux pumps and por-
ins. Furthermore fluoroquinolone resistance can also bee distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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qnr that express the pentapeptide repeat proteins. These
proteins protect the quinolone targets (DNA gyrase or
topoisomaerase IV enzymes) from the inhibitory activity
of fluoroquinolone antibiotics [5, 6]. In view of the genetic
heterogeneity variants of qnrA, B and S-like genes share
94 % to 99 %, 85 % to 99 % and 90 % nucleotide identity
respectively [7].
In addition K. pneumoniae has been reported to produce
clinically important carbapenemases; such as Ambler class
B metallo-β-lactamases (NDM), the class A enzymes (KPC)
and the class D oxacillinase enzymes (OXA-48) [8, 9].
Following the rise in the use of cephalosporins in hospi-
tals; the incidence of infections caused by ESBL-producing
K. pneumoniae has soared [2, 10]. Resistance to 3rd gener-
ation cephalosporins is predominantly associated with the
presence of blaCTX-M genes located on plasmids [11]. There-
fore plasmid mediated resistance to fluoroquinolones among
ESBL producing K. pneumoniae is alarming as it facilitates
therapy failure. Moreover; the exchange of the genetic infor-
mation among bacterial species threatens the efficacy of
fluoroquinolones and increases the dependency on carba-
penem antibiotics for treatment. The purpose of the present
study was to determine the prevalence of plasmid-mediated
fluoroquinolone resistance in ESBL-producing K. pneumo-
niae in hospitalized patients in Kuwait.Material and methods
Bacterial isolates
In-patient clinical samples were collected from the micro-
biology laboratories of three major governmental hospi-
tals that serve the six governorates of Kuwait, namely
Al-Ahmadi hospital, Al-Amiri hospital and Adan hospital.
All three hospitals are tertiary health care providers with
bed capacities of 300, 500 and 600, respectively. The aver-
age number of specimens processed every day in each
hospital varies from 500 to 700 which includes samples
from out-patient and in-patient specialists units. A table
was created based on the patients’ records containing
information such as age, gender, hospital, and type of
specimen. Specimens were processed by clinical staff
members of the diagnostic microbiology laboratories
using standard protocols. The species identification was
carried out by the API (bioMérieux, Marcy l’Etoile, France)
and the VITEK 2 systems (Vitek AMS; bioMérieux Vitek
Systems Inc., Hazelwood, MO, USA). The results were an-
alyzed according to the Clinical and Laboratory Standards
Institute (CLSI) (2012) guidelines [12]. The isolates were
stored in 10 % skim milk at −70 °C.Susceptibility testing
Antibiotic susceptibility tests were performed by the Kirby-
Bauer method disc diffusion test following the CLSI (2012)criteria and recommendations [12]. The antibiotics
tested were ampicillin, ampicillin/sulbactam, amoxicillin,
amoxicillin/clavulanic acid, piperacillin/tazobactam, cef-
tazidime, cefepime, ceftriaxone, cefazolin and cefuroxime.
The Minimum Inhibitory Concentration (MIC) was deter-
mined by agar dilution method and E-test when available
for the following antibiotics: trimethoprim gentamicin,
cefotaxime, imipenem, meropenem, ciprofloxacin, levo-
floxacin and tetracycline. Isolates that showed resistance
to at least three classes of antibiotics were considered as
MDR. Isolates that were detected as resistant to cefoxitin
were further investigated for the presence of an ampC
β-lactamase by using multiplex PCR [13, 14].
Double-disc synergy method
ESBLs were detected as previously described using the disc
approximation and double-disc synergy methods and con-
firmed with cefotaxime and ceftazidime E-test ESBL strips
(AB Biodisk, Biomerieux-diagnostics, Durham, NC, USA)
[2]. For the disc approximation test, clavulanate diffusion
from an amoxicillin–clavulanate (AMC30) disc was used to
test for synergy with cefotaxime, ceftazidime, cefuroxime,
cefepime and cefixime (Oxoid) as described previously
[15]. For the double-disc synergy test, a ceftazidime disc
(30 μg) was placed 30 mm away from a disc containing
amoxicillin–clavulanate (60/10 μg). ESBL production was
considered positive when an enhanced zone of inhib-
ition was visible between the β-lactam and β-lactamase
inhibitor-containing discs. For the E-test, ESBL strips con-
taining ceftazidime and ceftazidime–clavulanate and strips
containing cefotaxime and cefotaxime–clavulanate were
used to determine the MIC ratio according to the manufac-
turer's instructions (AB Biodisk, Biomerieux-diagnostics,
Durham, NC, USA). Cultures were incubated aerobically at
37 °C for 18–24 h. CTX-M-15 β-lactamase enzyme displays
a catalytic activity toward ceftazidime.
Detection of bla genes and other resistance determinants
The presence of resistant genes (listed below) were investi-
gated by PCR assays as previously reported [16]. PCR was
conducted in a GeneAmp 9700 (Perkin-Elmer, Illinois,
USA) system using the conditions specified for each primer;
corresponding to the source references. The resistant genes
investigated were blaTEM-1, blaSHV, blaCTX-M-like, blaNDM,
blaOXA-1, qnrA, qnrB, qnrS, aac(6′)-Ib Ib-cr, gyrA, parC,
gyrB, parE, intI1, intI2, blaKPC, blaVIM, blaIMP, blaOXA-48,
and ampC. The detection of blaPER, blaGES and blaVEB was
performed by PCR according to Opazo et al. [17].
Isolates resistant to ciprofloxacin and for which the cef-
taxidime or cefotaxime MICs were >8 mg/L were screened
for ESBLs and qnr genes. Double disc and combination disc
tests were used for ESBLs confirmation.
Amplified PCR products were purified with Qiagen puri-
fication kit (Qiagen, Limburg Netherlands) according to the
Table 1 The total number of ESBL producing Enterobacteriaceae isolates containing qnr genes during this study
Hospital Enterobacteriaceae
(ESBL producers)
Escherichia coli Enterobacter cloacae Proteus mirabilis Klebseilla oxytoca Klebsiella pneumoniae qnr positive K.
pneumoniae
Amiri 480 383 (80 %) 1 (0.2 %) 18 (3.8 %) 6 (1 %) 72 (15 %) 5 (6.9 %)
KOC 137 83 (61 %) 6 (4 %) 7 (5 %) 4 (3 %) 37 (27 %) 10 (2.7 %)
Adan 215 140 (65 %) 4 (1.8 %) 3 (1.4 %) 4 (1.8 %) 64 (30 %) 12 (18.8 %)
Total 832 606 (73 %) 11 (1.3 %) 28 (3 %) 14 (1.7 %) 173 (21 %) 27 (15.6 %)
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quenced by automated ABI3100 DNA sequencer (Applied
Biosystems, Foster City, CA, USA). The BLAST program
of the National Centre for Biotechnology Information
(http://www.ncbi.nlm.nih.gov) was used to search and
compare databases for similar nucleotide sequences.
Pulsed-Field Gel Electrophoresis (PFGE)
PFGE was performed by using the restriction enzyme
XbaI [18], with a run time of 20 h and switch times of 5
to 50 and 5 to 35 s at 14 °C and 6 V/cm (CHEF-DR IITable 2 The list of K. pneumoniae isolates



























NA Not availableSystem; Bio-Rad, Hercules, CA, USA). The PFGE profiles
were analyzed by using BioNumerics software version 7.1
(Applied Maths, Sint-Martens-Latem, Belgium). Statistics
was added at the end of the methods section.Statistical analysis
Out of the total number of isolates included hereby, the
percentage of the different ESBL-producing bacteria were
calculated in each of the three hospitals participating in
the study.Gender Age Species
M NA K. pneumoniae
M NA K. pneumoniae
M NA K. pneumoniae
F 33 K. pneumoniae
M 76 K. pneumoniae
F 33 K. pneumoniae
F 78 K. pneumoniae
M 84 K. pneumoniae
M 77 K. pneumoniae
F 77 K. pneumoniae
M 79 K. pneumoniae
F 8 K. pneumoniae
M 82 K. pneumoniae
F 47 K. pneumoniae
F 14 K. pneumoniae
F 36 K. pneumoniae
F 36 K. pneumoniae
F 90 K. pneumoniae
F 58 K. pneumoniae
F 72 K. pneumoniae
F 60 K. pneumoniae
M 59 K. pneumoniae
M 52 K. pneumoniae
M 78 K. pneumoniae
F 65 K. pneumoniae
M 81 K. pneumoniae
Table 3 The profiles of qnr positive K. pneumoniae isolates and
other resistance genes studied
Profiles of the antibiotic resistance genes No. of isolates
qnrB1, bla CTX-M-15 2
qnrB1, bla CTX-M-2, bla SHV, aac(6′)-Ib-cr 1
qnrB1, bla CTX-M-15, bla SHV, aac(6′)-Ib-cr 3
qnrS, bla CTX-M-2, bla TEM-1, bla SHV, aac(6′)-Ib-cr 1
qnrS, bla CTX-M-15, bla TEM-1, bla SHV, aac(6′)-Ib-cr 4
qnrA2, bla CTX-M-15, bla TEM-1, bla SHV, aac(6′)-Ib-cr 1
qnrB1, bla CTX-M-15, bla TEM-1, bla SHV, aac(6′)-Ib-cr 15
Total 27
Vali et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:34 Page 4 of 6DNA profiles were analysed by the unweighted pair
method with arithmetic average (UPGMA) using Bio-
Numerics v.7.1. The development of the algorithms ne-
cessary for the comparison of fingerprinting profiles of
isolates was based on the Dice correlation coefficient.
The hierarchic Cluster analysis and phylogenetic trees
were subsequently analysed with an optimization of 1.0 %
and a tolerance of 1 %. Isolates were considered to belong




All three governmental hospitals participated during our
study period from 2010 to 2012; however there were in-
consistencies in the level of strain contribution from each
hospital. Therefore under-representation of ESBL-mediated
K. pneumoniae might exist. A total of 832 ESBL-producing
Enterobacteriaceae isolates were obtained Table 1. They
comprised of 606 Escherichia coli (73 %), 11 Enterobacter
cloacae (1.3 %), 28 Proteus mirabilis (3 %), 14 Klebsiella
oxytoca (1.7 %) and 173 Klebsiella pneumoniae (21 %).Fig. 1 PFGE showing the relationship between DNA banding patternsThe antibiotic sensitivity testing for K. pneumoniae
isolates was performed followed by double-disc synergy
tests. The results were confirmed with PCR and sequen-
cing the product.
From the total of 173 (21 %) ESBL-producing K. pneu-
moniae qnr genes were identified in 27 (15.6 %) isolates.
The distribution of the isolates is presented in Table 2.
Sensitivity to antimicrobial agents
All the 27 qnr positive isolates were resistant to ampicillin
(MIC > 16), ciproflaxoacin (MIC > 4), cefotaxime (MIC > 4),
ceftazidime (MIC > 4), ceftriaxone (MIC > 4), and gentami-
cin (MIC > 16); but sensitive to imipenem (MIC > 1) and
meropenem (MIC > 1).
Sequencing the PCR products showed the distribution
of the resistance determinants (Table 3). blaCTX-M-15 was
detected in 25 (93 %), blaCTXM-2 in 2 (7 %), blaTEM in 21
(78 %), blaSHV and aac(6′)-Ib Ib-cr gene was found in 26
(96 %) isolates. Twenty one (78 %) isolates contained all
three bla genes. From the 27 K. pneumonia isolates only
1 (3.7 %) contained qnrA2, 21 harbored qnrB1 (78 %)
and 5 (18.5 %) contained qnrS. Class I integrons (intI1)
was detected in 25 (93 %) isolates but class II integrons
(intI2) was not found in any of the isolates tested. blaKPC,
blaVIM, blaPER, blaGES, blaVEB, blaIMP, blaOXA1, blaOXA48
and ampC were not detected in this study. No mutations
were found in gyrA and parC.
PFGE
PFGE showed diverse profiles among the isolates tested
(Fig. 1). Only two isolates (KOC 7 and KOC 64) from
urinary tract infection had identical PFGE patterns. The
majority of isolates with similar qnr genes; displayed similar
antimicrobial resistance phenotypes but their PFGE pro-
files were not identical. In total three isolates (ADA-45,
ADA-49 and KOC-37) were not typable by PFGE.
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In the present study we detected a similar rate of ESBL-
producing K. pneumoniae (21 %) as previously reported
(28 %) [19]. However, we found 15.6 % (27/173) of
ESBL-producing K. pneumoniae contained a plasmid me-
diated qnr gene. Previous research undertaken in Kuwait
in 2007 did not identify either qnrA or qnrS in ESBL-
producing Enterobacteriaceae and reported a low preva-
lence of 4.7 % (3 out of 64 isolates) of qnrB in E. coli [7].
Here we identified qnr A, B and S in ESBL-producing K.
pneumonia. The incidence rate of 15.6 % qnr in Kuwait
compared to other countries in Asia such as Iran (30.4 %)
[20]. Thailand (34.6 %) [21], Malaysia (37 %) [22], India
(67 %) [23] and Saudi Arabia (44 %) [24] is considerably
lower.
The key findings in our study are the emergence of
qnrA2 in the Middle East for the first time and also the
spread of qnrS among the clinical ESBL-producing K.
pneumonia isolates in Kuwait. qnrA is the first plasmid-
mediated quinolone resistance identified however, in K.
pneumoniae it is not as widespread as qnrB [25]. qnrA
confers resistance to quinolones such as nalidixic acid
and increases minimum inhibitory concentration (MIC)
values of fluoroquinolone up to 20-folds [26]. It has also
been shown that when both qnrA and aac- (6`)-Ib-cr are
present in the same cell, the level of ciprofloxacin resist-
ance is increased fourfold more than that conferred by
qnrA alone [5]. Therefore the detection of qnrA2 gene in
an ESBL producing K. pneumoniae from the catheter tip
of a 14 year old female patient was alarming and a chal-
lenge for empirical antibiotic therapy such as fluoroqui-
nolones in clinical settings. The rise of plasmid-
mediated fluoroquinolone resistance is concerning for
antimicrobial treatment of K. pneumoniae whereby the
only option left will be carbapenems.
In this study blaCTX-M-15 was the predominant β-
lactamase and in 93 % of the cases (25 out of 27 isolates)
it was associated with the presence of aac(6)-1b-cr. We also
identified qnrB1 and qnrS in isolates harbouring aac(6′)-Ib
Ib-cr and blaCTX-M. These isolates were resistant to penicil-
lins, most cephalosproins, β-lactamase inhibitors as well
as fluoroquinolones posing a risk to combination β-
lactam/β-lactamase inhibitor therapy. The correlation
between ESBL and ciprofloxacin resistance is an indication
of the important contribution of the plasmid-mediated re-
sistance to fluoroquinolone resistance in this region.
Urine samples comprised 67 % (18/27) of the specimens
followed by wound swabs 15 % (4/27). We did not find
any correlation between antimicrobial resistance char-
acteristics or specimen type and PFGE profiles. In fact
overall the PFGE profiles of the tested isolates were di-
verse implying that the spread of qnr genes is not con-
centrated to only a specific clonal lineage. A detailed
longitudinal study is required to identify the clonalidentity of ESBL-producing qnr-positive K. pneumonia
isolates.
Conclusion
This manuscript reports the genotypic variation among
strains of qnr positive K. pneumonieae in hospitalized
patients in Kuwait. The presence of qnr and aac-(6`)-Ib-cr
genes especially when they co-exist in ESBL-producing
isolates contribute to the increase in fluoroquinolone
resistance.
In conclusion the clinical importance of our findings is
that the circulating MDR plasmids that contain qnr, aac-
(6`)-Ib-cr and bla genes are concerning in hospitals as
they increase the chances of K. pneumoniae adaptability
to environmental pressures such as antibiotics. If guide-
lines are not in place regarding the strict use of antibiotics
we will face antimicrobial therapy failure in hospitalized
patients. Continuous monitoring of plasmid mediated
fluoroquinolone ESBL-producing Enterobactericeae in
clinical settings is crucial.
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